Invivyd, Inc.
$1.68
▼
-3.76%
2026-04-21 07:37:01
www.invivyd.com
NGM: IVVD
Explore Invivyd, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$492.08 M
Current Price
$1.68
52W High / Low
$3.07 / $0.46
Stock P/E
—
Book Value
$0.86
Dividend Yield
—
ROCE
-22.89%
ROE
-33.97%
Face Value
—
EPS
$-0.3
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
122
Beta
0.74
Debt / Equity
1.03
Current Ratio
7.24
Quick Ratio
7.24
Forward P/E
-8
Price / Sales
9.32
Enterprise Value
$273.17 M
EV / EBITDA
-4.98
EV / Revenue
5.11
Rating
Strong Buy
Target Price
$10
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Relay Therapeutics, Inc. | $16.4 | — | $3 B | — | -50.82% | -41.12% | $17.32 / $2.53 | $3.26 |
| 2. | SeaStar Medical Holding Corporation | $4.63 | — | $16.77 M | — | -116.89% | -2.95% | $13.4 / $2.07 | $2.71 |
| 3. | KALA BIO, Inc. | $0.2 | — | $185.9 M | — | -88.86% | -388.29% | $20.6 / $0.15 | $-1.17 |
| 4. | Recursion Pharmaceuticals, Inc. | $3.69 | — | $1.95 B | — | -48.86% | -59.54% | $7.18 / $2.8 | $2.14 |
| 5. | PolyPid Ltd. | $4.69 | — | $89.5 M | — | -226.3% | -3.66% | $5.12 / $2.44 | $0.6 |
| 6. | Niagen Bioscience, Inc. | $4.87 | 22.44 | $389.99 M | — | 16.53% | 28.35% | $14.69 / $4.16 | $0.96 |
| 7. | X4 Pharmaceuticals, Inc. | $4.19 | — | $372.04 M | — | -32.82% | -75.99% | $6.63 / $1.35 | $2.05 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 17.21 M | 13.13 M | 11.79 M | 11.3 M | 13.82 M | — |
| Operating Profit | -12.55 M | -11.02 M | -15.06 M | -16.92 M | -19.23 M | — |
| Net Profit | -11.07 M | -10.47 M | -14.66 M | -16.29 M | -18.44 M | — |
| EPS in Rs | -0.04 | -0.04 | -0.05 | -0.06 | -0.07 | -0.51 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 53.43 M | 25.38 M | 0 M | 0 M |
| Operating Profit | -55.56 M | -176.88 M | -207.78 M | -226.26 M |
| Net Profit | -52.49 M | -169.93 M | -198.64 M | -241.32 M |
| EPS in Rs | -0.19 | -0.6 | -0.7 | -0.85 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 276.88 M | 129.51 M | 229.18 M | 383.17 M |
| Total Liabilities | 35.34 M | 61.98 M | 51.71 M | 27.2 M |
| Equity | 241.54 M | 67.54 M | 177.47 M | 355.97 M |
| Current Assets | 247.47 M | 100.68 M | 224.88 M | 376.92 M |
| Current Liabilities | 34.16 M | 61.98 M | 50.29 M | 25.03 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -58.13 M | -170.49 M | -173.16 M | -219.99 M |
| Investing CF | -0.15 M | -0.14 M | 280.68 M | -230.67 M |
| Financing CF | 215.63 M | 39.33 M | 1.04 M | 0.51 M |
| Free CF | -58.29 M | -170.63 M | -173.78 M | -221.69 M |
| Capex | -0.15 M | -0.14 M | -0.61 M | -1.71 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 14.46% | 17.68% | — | — |
| Profit Margin % | -669.42% | — | — | — |
| Operating Margin % | -696.8% | — | — | — |
| Gross Margin % | 93.63% | — | — | — |
| EBITDA Margin % | -684.54% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.